Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression

Detalhes bibliográficos
Autor(a) principal: Dias,Vitor Loureiro
Data de Publicação: 2022
Outros Autores: Storrer,Karin Mueller
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Jornal Brasileiro de Pneumologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132022000200201
Resumo: ABSTRACT Objective To characterize the prevalence of latent tuberculosis infection (LTBI) in patients with interstitial lung diseases (ILDs) requiring immunosuppression. Only 5 to 10% of individuals infected with Mycobacterium tuberculosis develop tuberculosis, and certain groups of patients have an increased risk of illness, such as the immunocompromised. Patients with ILDs are frequently treated with immunosuppressants and, therefore, might have a higher risk of developing the disease. Methods Prospective study conducted at the ILD reference center of the Federal University of Paraná from January 2019 to December 2020. The screening of LTBI was performed with the use of the tuberculin skin test (TST). Results The sample consisted of 88 patients, of whom 64.8% were women, with a mean age of 61.4 years. The most frequent diagnoses were autoimmune rheumatic disease ILD (38.6%) and hypersensitivity pneumonitis (35.2%). The most common immunosuppressant in use at the time of the TST was prednisone, either in combination with mycophenolate (19.3%) or alone (17.1%). The majority of participants had fibrotic lung disease, characterized by a reticular interstitial pattern on chest computed tomography (79.5%) and moderate to severe functional impairment (mean FVC 69.2%). A prevalence of LTBI of 9.1% (CI 95%, 2.1%-15.1%) was found, with a TST median of 13. Conclusion Patients with ILD who are treated with immunosuppressants are not commonly screened for LTBI, despite being under a greater risk of progression to active disease. This study suggests the need for a more cautious approach to these patients.
id SBPT-1_64e01b28ca16c0951921f00c48b09371
oai_identifier_str oai:scielo:S1806-37132022000200201
network_acronym_str SBPT-1
network_name_str Jornal Brasileiro de Pneumologia (Online)
repository_id_str
spelling Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppressionLatent tuberculosis infectionInterstitial lung diseasesImmunosuppressionTuberculin testABSTRACT Objective To characterize the prevalence of latent tuberculosis infection (LTBI) in patients with interstitial lung diseases (ILDs) requiring immunosuppression. Only 5 to 10% of individuals infected with Mycobacterium tuberculosis develop tuberculosis, and certain groups of patients have an increased risk of illness, such as the immunocompromised. Patients with ILDs are frequently treated with immunosuppressants and, therefore, might have a higher risk of developing the disease. Methods Prospective study conducted at the ILD reference center of the Federal University of Paraná from January 2019 to December 2020. The screening of LTBI was performed with the use of the tuberculin skin test (TST). Results The sample consisted of 88 patients, of whom 64.8% were women, with a mean age of 61.4 years. The most frequent diagnoses were autoimmune rheumatic disease ILD (38.6%) and hypersensitivity pneumonitis (35.2%). The most common immunosuppressant in use at the time of the TST was prednisone, either in combination with mycophenolate (19.3%) or alone (17.1%). The majority of participants had fibrotic lung disease, characterized by a reticular interstitial pattern on chest computed tomography (79.5%) and moderate to severe functional impairment (mean FVC 69.2%). A prevalence of LTBI of 9.1% (CI 95%, 2.1%-15.1%) was found, with a TST median of 13. Conclusion Patients with ILD who are treated with immunosuppressants are not commonly screened for LTBI, despite being under a greater risk of progression to active disease. This study suggests the need for a more cautious approach to these patients.Sociedade Brasileira de Pneumologia e Tisiologia2022-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132022000200201Jornal Brasileiro de Pneumologia v.48 n.2 2022reponame:Jornal Brasileiro de Pneumologia (Online)instname:Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)instacron:SBPT10.36416/1806-3756/e20210382info:eu-repo/semantics/openAccessDias,Vitor LoureiroStorrer,Karin Muellereng2022-03-23T00:00:00Zoai:scielo:S1806-37132022000200201Revistahttp://www.jornaldepneumologia.com.br/default.aspONGhttps://old.scielo.br/oai/scielo-oai.php||jbp@jbp.org.br|| jpneumo@jornaldepneumologia.com.br1806-37561806-3713opendoar:2022-03-23T00:00Jornal Brasileiro de Pneumologia (Online) - Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)false
dc.title.none.fl_str_mv Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression
title Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression
spellingShingle Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression
Dias,Vitor Loureiro
Latent tuberculosis infection
Interstitial lung diseases
Immunosuppression
Tuberculin test
title_short Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression
title_full Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression
title_fullStr Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression
title_full_unstemmed Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression
title_sort Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression
author Dias,Vitor Loureiro
author_facet Dias,Vitor Loureiro
Storrer,Karin Mueller
author_role author
author2 Storrer,Karin Mueller
author2_role author
dc.contributor.author.fl_str_mv Dias,Vitor Loureiro
Storrer,Karin Mueller
dc.subject.por.fl_str_mv Latent tuberculosis infection
Interstitial lung diseases
Immunosuppression
Tuberculin test
topic Latent tuberculosis infection
Interstitial lung diseases
Immunosuppression
Tuberculin test
description ABSTRACT Objective To characterize the prevalence of latent tuberculosis infection (LTBI) in patients with interstitial lung diseases (ILDs) requiring immunosuppression. Only 5 to 10% of individuals infected with Mycobacterium tuberculosis develop tuberculosis, and certain groups of patients have an increased risk of illness, such as the immunocompromised. Patients with ILDs are frequently treated with immunosuppressants and, therefore, might have a higher risk of developing the disease. Methods Prospective study conducted at the ILD reference center of the Federal University of Paraná from January 2019 to December 2020. The screening of LTBI was performed with the use of the tuberculin skin test (TST). Results The sample consisted of 88 patients, of whom 64.8% were women, with a mean age of 61.4 years. The most frequent diagnoses were autoimmune rheumatic disease ILD (38.6%) and hypersensitivity pneumonitis (35.2%). The most common immunosuppressant in use at the time of the TST was prednisone, either in combination with mycophenolate (19.3%) or alone (17.1%). The majority of participants had fibrotic lung disease, characterized by a reticular interstitial pattern on chest computed tomography (79.5%) and moderate to severe functional impairment (mean FVC 69.2%). A prevalence of LTBI of 9.1% (CI 95%, 2.1%-15.1%) was found, with a TST median of 13. Conclusion Patients with ILD who are treated with immunosuppressants are not commonly screened for LTBI, despite being under a greater risk of progression to active disease. This study suggests the need for a more cautious approach to these patients.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132022000200201
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132022000200201
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.36416/1806-3756/e20210382
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Pneumologia e Tisiologia
publisher.none.fl_str_mv Sociedade Brasileira de Pneumologia e Tisiologia
dc.source.none.fl_str_mv Jornal Brasileiro de Pneumologia v.48 n.2 2022
reponame:Jornal Brasileiro de Pneumologia (Online)
instname:Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)
instacron:SBPT
instname_str Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)
instacron_str SBPT
institution SBPT
reponame_str Jornal Brasileiro de Pneumologia (Online)
collection Jornal Brasileiro de Pneumologia (Online)
repository.name.fl_str_mv Jornal Brasileiro de Pneumologia (Online) - Sociedade Brasileira de Pneumologia e Tisiologia (SBPT)
repository.mail.fl_str_mv ||jbp@jbp.org.br|| jpneumo@jornaldepneumologia.com.br
_version_ 1750318348247236608